Real Chemistry’s Latest IRIS Report Reveals Higher Costs to Consumers of GLP-1 Agonist Treatments Obtained in “Gray Market” vs. Through Traditional Healthcare Providers
Online providers and medical spas are charging consumers more than traditional healthcare channels NEW YORK (July 22, 2024) – IRIS by Real Chemistry today released...
